GlassScriptPhysician profile
Richard S Witlin
NPI 1063459212
$4,208.62
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,047 · 2020: $601 · 2021: $546 · 2022: $14.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,140.84 | 2019-2021 | |
| Alcon Vision LLC | $874.78 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $456.01 | 2019-2021 | |
| Glaukos Corporation | $218.64 | 2019-2020 | |
| Allergan, INC. | $153.71 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $137.93 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $55.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.94 | 2019-2021 | |
| Eyepoint US, INC. | $35.48 | 2019-2021 | |
| Shire North American Group INC | $26.33 | 2019 | |
| Sight Sciences, INC. | $16.40 | 2019 | |
| Bausch & Lomb Americas INC. | $14.72 | 2022 | |
| Omeros Corporation | $14.24 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Witlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.